Section Arrow
NVCR.NASDAQ
- NovoCure Limited
Quotes are at least 15-min delayed:2025/01/21 05:37 EST
Last
 26.17
+0.15 (+0.58%)
Day High 
27.105 
Prev. Close
26.02 
1-M High
34.13 
Volume 
1.18M 
Bid
26.1
Ask
26.97
Day Low
25.66 
Open
25.66 
1-M Low
25.46 
Market Cap 
2.82B 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 28.12 
20-SMA 29.5 
50-SMA 25.04 
52-W High 34.13 
52-W Low 11.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.39/-2.48
Enterprise Value
3.41B
Balance Sheet
Book Value Per Share
3.33
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
509.34M
Operating Revenue Per Share
4.66
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
QSIQuantum-Si2.24-0.3-11.81%-- 
SENSSenseonics Holdings0.8479-0.0271-3.10%-- 
BDMDBaird Medical Investment Holdings Ltd8.85+3.43+63.28%15.32PE
BMRABiomerica0.64-0.066-9.35%-- 
MDTMedtronic plc88.08+0.92+1.06%26.61PE
Quotes are at least 15-min delayed:2025/01/21 05:37 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatmentof solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derivesmajority of its revenue from the United States and rest from Germany, Japan and other markets.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.